Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
SPONSOR/MONITOR'S REPORT NUMBER(S)12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTES
ABSTRACTThis is an Exploration -Hypothesis Development Award (EHD) in which we modeled in a mouse model system the natural androgen decline in the aging male (ADAM) as it occurs after the age of 40 years in humans. ADAM coincides with a dramatic increase in the prostate cancer incidence in all population groups. To date we have collected all biological specimens and are in the process of detailed analyses. We have also explored androgen receptor (AR) signaling in pilot studies to allow a better understanding of this axis in ADAM. COETZEE, Gerhard A. Annual progress report W81XWH-04-1-0049 COETZEE, Gerhard A. Annual progress report W81XWH-04-1-0049Introduction:The androgen receptor (AR), a ligand-dependent nuclear transcription factor, plays a vital role in prostate cancer (PCa) development by regulating the transcription of target genes involved in cell cycle regulation and apoptosis. Physician-induced androgen ablation (castration or AR inhibition) selects for aberrant AR signaling mechanisms in recurrent tumors that include AR and p160 cofactor overexpression and ligand-independent activation of the AR. The natural androgen decline in the aging Male (ADAM) occurs after the age of 40 years, which coincides with the dramatic increase in the prostate cancer incidence in all population groups.The viability of the following hypothesis is being evaluated: Prostate cancer progression to androgen independence with age is a consequence of ADAM. ADAM, in turn, selects for prostate cancer cell clones with hypersensitive AR signaling capabilities due to AR amplification, changes in cofactor expression profiles or non-steroidal activation of the AR. A novel outcome of this work may be the realization that inappropriate AR signaling contributes to PCa risk with age and that the AR is a legitimate target not only for prostate cancer treatments, but also possibly for prevention strategies via hormone replacement with advancing age.
Body:A single hypothesis is being evaluated (see ab...